Avances en la Investigación sobre la Tormenta de Citoquinas: Una Revisión Sistemática de Literatura
DOI:
https://doi.org/10.65415/rcs.v3i1.5Palabras clave:
Tormenta de citoquinas; COVID-19; IL-6; Terapias inmunológicas; Biomarcadores.Resumen
La tormenta de citoquinas es una respuesta inmunológica exacerbada que ha sido identificada como un factor determinante en la progresión de enfermedades infecciosas como el COVID-19 y en terapias inmunológicas como el tratamiento con células CAR-T. Este estudio presenta una revisión sistemática de literatura de 20 artículos publicados entre 2020 y 2025. Se identifican y analizan las principales líneas de investigación, biomarcadores emergentes, implicaciones clínicas y enfoques terapéuticos. Los hallazgos revelan la centralidad del interleucina-6 (IL-6), el papel de ACE2 y la utilidad de fármacos como tocilizumab y anakinra. Esta revisión permite sintetizar el estado actual del conocimiento, aportar orientaciones clínicas y proponer futuras líneas de investigación.
Descargas
Referencias
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., & Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of Clinical Investigation, 130(5), 2620-2629. https://doi.org/10.1172/JCI137244
Conti, P., Ronconi, G., Caraffa, A., Gallenga, C., Ross, R., Frydas, I., & Kritas, S. (2020). Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): Anti-inflammatory strategies. Journal of Biological Regulators and Homeostatic Agents, 34(2), 327-331. https://doi.org/10.23812/CONTI-E
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., Marron, T. U., Xie, H., Patel, M., Tuballes, K., Van Oekelen, O., Rahman, A., Kovatch, P., Aberg, J. A., Schadt, E., … Gnjatic, S. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 26(10), 1636-1643. https://doi.org/10.1038/s41591-020-1051-9
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England), 395(10223), 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124(2), 188-195. https://doi.org/10.1182/blood-2014-05-552729
Liu, T., Zhang, J., Yang, Y., Zhang, L., Ma, H., Li, Z., Zhang, J., Cheng, J., Zhang, X., Wu, G., & Yi, J. (2020). The potential role of IL-6 in monitoring coronavirus disease 2019 (p. 2020.03.01.20029769). medRxiv. https://doi.org/10.1101/2020.03.01.20029769
McGonagle, D., Sharif, K., O’Regan, A., & Bridgewood, C. (2020). The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmunity Reviews, 19(6), 102537. https://doi.org/10.1016/j.autrev.2020.102537
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J., & HLH Across Speciality Collaboration, UK. (2020). COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet (London, England), 395(10229), 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
Moore, J. B., & June, C. H. (2020). Cytokine release syndrome in severe COVID-19. Science (New York, N.Y.), 368(6490), 473-474. https://doi.org/10.1126/science.abb8925
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ (Clinical Research Ed.), 372, n71. https://doi.org/10.1136/bmj.n71
Ragab, D., Salah Eldin, H., Taeimah, M., Khattab, R., & Salem, R. (2020). The COVID-19 Cytokine Storm; What We Know So Far. Frontiers in Immunology, 11, 1446. https://doi.org/10.3389/fimmu.2020.01446
Sánchez-García, S., Povo-Retana, A., Marin, S., Madurga, S., Fariñas, M., Aleixandre, N., Castrillo, A., de la Rosa, J. V., Alvarez-Lucena, C., Landauro-Vera, R., Prieto, P., Cascante, M., & Boscá, L. (2025). Immunometabolic Effect of Nitric Oxide on Human Macrophages Challenged With the SARS-CoV2-Induced Cytokine Storm. A Fluxomic Approach. Advanced Healthcare Materials, 14(1), e2401688. https://doi.org/10.1002/adhm.202401688
Shimizu, M. (2024). Clinical Features of Cytokine Storm Syndrome. Advances in Experimental Medicine and Biology, 1448, 33-42. https://doi.org/10.1007/978-3-031-59815-9_4
Sun, X., Wang, T., Cai, D., Hu, Z., Chen, J., Liao, H., Zhi, L., Wei, H., Zhang, Z., Qiu, Y., Wang, J., & Wang, A. (2020). Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine & Growth Factor Reviews, 53, 38-42. https://doi.org/10.1016/j.cytogfr.2020.04.002
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020). Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Frontiers in Immunology, 11, 1708. https://doi.org/10.3389/fimmu.2020.01708
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012). Into the eye of the cytokine storm. Microbiology and Molecular Biology Reviews: MMBR, 76(1), 16-32. https://doi.org/10.1128/MMBR.05015-11
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., Zhang, X., Pan, A., & Wei, H. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences of the United States of America, 117(20), 10970-10975. https://doi.org/10.1073/pnas.2005615117
Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. The Journal of Infection, 80(6), 607-613. https://doi.org/10.1016/j.jinf.2020.03.037
Yr, G., Qd, C., Zs, H., Yy, T., Sd, C., Hj, J., Ks, T., Dy, W., & Y, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—An update on the status. Military Medical Research, 7(1). https://doi.org/10.1186/s40779-020-00240-0
Zhang, C., Wu, Z., Li, J.-W., Zhao, H., & Wang, G.-Q. (2020). Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. International Journal of Antimicrobial Agents, 55(5), 105954. https://doi.org/10.1016/j.ijantimicag.2020.105954
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet (London, England), 395(10229), 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2025 Research Club Scientia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
